NCT03304951已完成不适用
Interventioanl Study of the Sinopsys® Lacrimal Stent in Patients With Moderate to Severe Chronic Rhinosinusitis to Evaluate Safety and Performance for Direct Ethmoid Sinus Saline Irrigation and Ophthalmic Antibiotic/Steroid Delivery
Sinopsys Surgical2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2016年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- Demonstration of acute procedural/device success
研究概览
简要总结
The primary objective is to evaluate clinical data related to the safety and performance of the Sinopsys® Lacrimal Stent.
详细描述
The primary objective of this study is to evaluate the safety and performance of the Sinopsys® Lacrimal Stent in the treatment of patients with moderate to severe chronic chronic rhinosinusitis via direct ethmoid sinus saline irrigation and delivery of an ophthalmic antibiotic/steroid drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Investigator has determined that the potential study subject has moderate to severe chronic rhino sinusitis with ethmoid involvement and has failed medical therapy prior to enrollment.
- •Age ≥22 years The potential study subject meets the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) criteria for chronic rhino sinusitis (Rosenfeld, et al, 2007)
- •12 weeks or longer of two or more o f the following signs and symptoms:
- •Mucopurulent drainage (anterior, posterior or both)
- •Nasal Obstruction (congestion)
- •Facial pain-pressure-fullness, or
- •Decreased sense of smell and Inflammation si documents by one or more of the following findings:
- •Purulent (not clear) mucus or edema in the middle meatus or ethmoid region
- •Polyps in nasal cavity or the middle meatus, and/or
- •Radiographic imaging showing inflammation of the paranasal sinuses
- •SNOT-20 total raw score ≥ 41
- •Non-Contrast CT scan (coronal view) confirms depth of olfactory fossa is Keros classification 1or 2 (Gauba, Sleh, Dua, Agarwal, Ell, & Vize, 2006)
- •The potential study subject is capable of understanding and executing written informed consent (IC)
排除标准
- •Sinus opacification score of ≤ 8 or ≥ 18 measured using the CT derived Lund-Mackay scoring system
- •Isolated sinus disease evident on Non-Contrast CT scan that would unlikely to respond to target ethmoid treatment (e.g., isolated sphenoid or frontal disease).
- •Polyposis scored as 3 using the Modified Lund-Kennedy Score as follows:
- •3 = Polyps completely obstructing the nose
- •Prior ocular and/or sinus surgery that alter the boney anatomy or violate/enter the orbit or sinus (i.e. Fess, balloon sinuplasty). Minor procedures such as septoplasty or turbinectomy are not exclusions.
- •Prior surgical history, physical exam, nasal endoscopy, and /or imaging studies that suggest significant craniofacial deformity (such as facial anatomic abnormality from surgical intervention, trauma, and congenital or any other cause thus prohibiting adequate placement of the Sinopsys® Lacrimal Stent).
- •Presence of a sinonasal encepholocele as determined by Non-Contrast CT scan.
- •Presence of active HEENT infection including acute dacryocystitis, with the exception of baseline CRS (Chronic Rhinosinusitis) infection.
- •Febrile illness within 2 weeks of procedure and/or active pus from nose.
- •Any sign of active ophthalmic disease, infection or inflammation including the presence of severe ocular surface inflammatory disease as determined by ophthalmic and physical exam, which could be exacerbated by the presence of the device.
- •Current use of topical medications for the eye to treat an active ophthalmic disease.
- •Underlying medical condition that, in the opinion of the Investigator, would place the subject at high risk if PO or IV sedation (MAC or monitored anesthesia care) were used during the procedure.
- •Known silicone allergy
- •Documented diagnostic history of Cystic Fibrosis
- •Documented history of migraines and/or cluster headaches requiring treatment with anti-migraine medication.
- •Documented uncontrolled or poorly controlled seasonal or perennial allergies requiring daily anti-allergy oral, nasal or ophthalmic medications.
- •Tobacco, marijuana and /or e-vape inhaler use either currently or during the last 6 months
- •Documented history of bleeding disorders, for example, von Willebrand's disease or hemophilia.
- •Inability to stop thrombolytics or other anti-platelet medication prior to procedure day including but not limited to Coumadin (warfarin) for 5 days, Plavix (clopidogrel) for 3 days, ASA(aspirin)/NSAIDs/fish oil supplements for 10 days, Xeralta® (rivaroxaban) for 24 hours.
- •For contact lens wearers, inability to go without contact lenses for at least 10 days postoperatively.
- •Known use of any investigational ocular or sinusitis drug(s) or devices within 30 days prior to enrollment.
- •Investigator determination that the potential study subject is unable to comply with study procedures and /or follow-up, or provided informed consent.
- •Women of childbearing potential who test positive on the study-required urine pregnancy test and who are unwilling to practice a medically acceptable contraception regimen from screening through week 8 visit. Women who are documented as postmenopausal for at least 1 year (> 12 months since last menses) or are surgically sterilized, do not require testing.
- •Severe co-morbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, cognitive function, substance abuse, shortened life expectancy, vulnerable patient population, high surgical risk).
- •Currently involved in another clinical study where that participation may conflict or interfere with the treatment, follow-up or results of the clinical study.
研究组 & 干预措施
Synopsis® Lacrimal Stent
Experimental
The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
干预措施: Sinopsys® Lacrimal Stent (Device)
结局指标
主要结局
Demonstration of acute procedural/device success
时间窗: 8 Weeks
Success defined as successful placement of the Sinopsys® Lacrimal Stent and ability to create and maintain transcaruncular access to the ethmoid sinus with the Sinopsys® Lacrimal Stent for 8 weeks post procedure.
Evaluation of Clinical Success at Week 1, 4 and 8 weeks
时间窗: 8 Weeks
Using sterile saline eye drop irrigation and two 10-Day courses of ophthalmic antibiotic/steroid eye drops, defined as improvement in SNOT (Sino-Nasal Outcome Test)-20 compared to baseline.
次要结局
- Compare performance of Screening, 4, and 8 week follow up Modified Lund Kennedy nasal endoscopy scores(8 Weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
Sinopsys Lacrimal Stent Indicated for Sinus IrrigationEthmoid SinusitisNCT02297243Sinopsys Surgical9
暂停
不适用
Sinopsys Lacrimal Stent Study for Patients With Chronic Sinusitis or CRSChronic Sinus InfectionNCT03066908Sinopsys Surgical4
已完成
4 期
The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of EpiphoraEpiphoraNCT01010659Aurolab30
已完成
早期 1 期
The Sinopsys Lacrimal Stent for Lacrimal System Repair in EpiphoraEpiphoraNCT02240615Sinopsys Surgical10
已完成
1 期
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male VolunteersHealthy VolunteersAnti-Bacterial AgentsMethicillin-Resistant Staphylococcus AureusNCT01855048Intron Biotechnology, Inc.36